FI76255C - Foerfarande foer framstaellning av en antiviral foerbaettrad topisk olja-i-vatten-komposition av 9-(2-hydroxietoximetyl)guanin eller ett farmaceutiskt godtagbart salt eller ester daerav. - Google Patents
Foerfarande foer framstaellning av en antiviral foerbaettrad topisk olja-i-vatten-komposition av 9-(2-hydroxietoximetyl)guanin eller ett farmaceutiskt godtagbart salt eller ester daerav. Download PDFInfo
- Publication number
- FI76255C FI76255C FI812257A FI812257A FI76255C FI 76255 C FI76255 C FI 76255C FI 812257 A FI812257 A FI 812257A FI 812257 A FI812257 A FI 812257A FI 76255 C FI76255 C FI 76255C
- Authority
- FI
- Finland
- Prior art keywords
- acyclovir
- eller
- water
- formulation
- ester
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title description 9
- 150000003839 salts Chemical class 0.000 title description 7
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 title 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 69
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 69
- 229960004150 aciclovir Drugs 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000012071 phase Substances 0.000 claims description 19
- 239000003995 emulsifying agent Substances 0.000 claims description 17
- 150000005846 sugar alcohols Polymers 0.000 claims description 16
- 239000008346 aqueous phase Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 239000004358 Butane-1, 3-diol Substances 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 229960003511 macrogol Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 54
- 239000002674 ointment Substances 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 22
- 239000006071 cream Substances 0.000 description 21
- 239000003921 oil Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 239000000839 emulsion Substances 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 229940057995 liquid paraffin Drugs 0.000 description 10
- 229940082500 cetostearyl alcohol Drugs 0.000 description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 9
- 239000012188 paraffin wax Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- 229940031955 anhydrous lanolin Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940107931 zovirax Drugs 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920002329 Gum anima Polymers 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- -1 i.e. Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003232 troxerutin Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8023645 | 1980-07-18 | ||
| GB8023645 | 1980-07-18 | ||
| GB8033218A GB2080106B (en) | 1980-07-18 | 1980-10-15 | Acyclovin preparations |
| GB8033218 | 1980-10-15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI812257L FI812257L (fi) | 1982-01-19 |
| FI76255B FI76255B (fi) | 1988-06-30 |
| FI76255C true FI76255C (fi) | 1990-03-14 |
Family
ID=26276273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI812257A FI76255C (fi) | 1980-07-18 | 1981-07-17 | Foerfarande foer framstaellning av en antiviral foerbaettrad topisk olja-i-vatten-komposition av 9-(2-hydroxietoximetyl)guanin eller ett farmaceutiskt godtagbart salt eller ester daerav. |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0044543B1 (en, 2012) |
| AR (1) | AR225680A1 (en, 2012) |
| AT (1) | AT381025B (en, 2012) |
| AU (1) | AU547391B2 (en, 2012) |
| BG (1) | BG60450B2 (en, 2012) |
| CA (1) | CA1172169A (en, 2012) |
| CS (1) | CS229674B2 (en, 2012) |
| CY (1) | CY1309A (en, 2012) |
| DD (1) | DD203464A5 (en, 2012) |
| DE (1) | DE3163982D1 (en, 2012) |
| DK (1) | DK149191C (en, 2012) |
| ES (1) | ES504046A0 (en, 2012) |
| FI (1) | FI76255C (en, 2012) |
| GB (1) | GB2080106B (en, 2012) |
| GR (1) | GR75104B (en, 2012) |
| HK (1) | HK95485A (en, 2012) |
| HU (1) | HU185936B (en, 2012) |
| IE (1) | IE51120B1 (en, 2012) |
| IL (1) | IL63351A (en, 2012) |
| IT (1) | IT1171399B (en, 2012) |
| MC (1) | MC1408A1 (en, 2012) |
| MY (1) | MY8600389A (en, 2012) |
| NO (1) | NO155038C (en, 2012) |
| NZ (1) | NZ197744A (en, 2012) |
| PH (1) | PH16308A (en, 2012) |
| PL (1) | PL135416B1 (en, 2012) |
| PT (1) | PT73391B (en, 2012) |
| RO (1) | RO82678A (en, 2012) |
| SG (1) | SG72085G (en, 2012) |
| ZW (1) | ZW17181A1 (en, 2012) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0095813A3 (en) * | 1982-06-01 | 1985-05-08 | THE PROCTER & GAMBLE COMPANY | Penetrating topical pharmaceutical compositions containing 9-(2-hydroxyethoxymethyl) guanine |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| GB8602346D0 (en) * | 1986-01-30 | 1986-03-05 | Wellcome Found | Antiviral combinations |
| GB8917959D0 (en) * | 1989-08-05 | 1989-09-20 | Beecham Group Plc | Pharmaceutical formulation |
| US6469015B1 (en) | 1990-01-26 | 2002-10-22 | Novartis International Pharmaceutical Ltd | Pharmaceutical formulation |
| GB9001886D0 (en) * | 1990-01-26 | 1990-03-28 | Beecham Group Plc | Pharmaceutical formulation |
| EP0561465B1 (en) * | 1992-03-20 | 1997-09-17 | Unichema Chemie B.V. | Release composition |
| DK169121B1 (da) * | 1992-09-09 | 1994-08-22 | Gea Farmaceutisk Fabrik As | Antiviralt virksom farmaceutisk olie-i-vand-emulsion indeholdende 9-[(2-hydroxyethoxy)methyl]guanin (acyclovir) eller et salt eller en ester deraf |
| DE4416674C2 (de) * | 1994-05-11 | 1997-01-30 | Rentschler Arzneimittel | Topische Zubereitung enthaltend Aciclovir |
| DE19517147C2 (de) * | 1995-05-10 | 1999-07-01 | Hexal Pharmaforschung Gmbh | Aciclovir-Zubereitung |
| AU2036297A (en) * | 1996-03-20 | 1997-10-10 | Glaxo Group Limited | Topical formulations of aciclovir |
| GB9611167D0 (en) * | 1996-05-29 | 1996-07-31 | Glaxo Group Ltd | Medicaments |
| GB9718568D0 (en) | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
| GB9718791D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Medicaments |
| ITMI981528A1 (it) * | 1998-07-03 | 2000-01-03 | Recordati Ind Chimica E Farma | Formulazioni topiche di aciclovir |
| US7223387B2 (en) | 1998-11-18 | 2007-05-29 | Medivir Ab | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| GB9828620D0 (en) * | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Medicaments |
| RU2179851C1 (ru) * | 2000-12-21 | 2002-02-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Противовирусный фармацевтический состав |
| RU2175230C1 (ru) * | 2001-01-23 | 2001-10-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция с противовирусной активностью и способ ее получения |
| FR2837102B1 (fr) * | 2002-03-18 | 2004-10-08 | Palbian Snc | Composition a l'etat de gel aqueux, procede de fabrication et utilisation pour la fabrication d'un medicament, notamment antiherpetique |
| CA2562190C (en) * | 2004-04-05 | 2012-08-21 | Laboratorios Liomont, S.A. De C.V. | Novel antiviral pharmaceutical composition |
| EP2005824A1 (de) † | 2007-06-21 | 2008-12-24 | Bayer CropScience AG | Wirkstoffsuspensionen in Glycerin |
| WO2017029298A1 (en) | 2015-08-17 | 2017-02-23 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A topical antiviral composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3892857A (en) * | 1972-11-24 | 1975-07-01 | Squibb & Sons Inc | Steroid formulation |
| ZA738657B (en) * | 1973-01-05 | 1974-10-30 | Hoffmann La Roche | Emulsions |
| GB1478009A (en) * | 1973-04-02 | 1977-06-29 | Glaxo Lab Ltd | Pharmaceutical compositions |
| US4199574A (en) * | 1974-09-02 | 1980-04-22 | Burroughs Wellcome Co. | Methods and compositions for treating viral infections and guanine acyclic nucleosides |
| GB1543907A (en) * | 1975-02-19 | 1979-04-11 | Dermal Labor Ltd | Steroid compositions |
| US3934013A (en) * | 1975-02-21 | 1976-01-20 | Syntex (U.S.A.) Inc. | Pharmaceutical composition |
| US4049802A (en) * | 1975-03-19 | 1977-09-20 | Research Corporation | Zinc sulfadiazine and its use in the treatment of burns |
| GB1554720A (en) * | 1975-07-10 | 1979-10-24 | Nyegaard & Co As | Pyridthione derivatives |
| US4144332A (en) * | 1976-01-05 | 1979-03-13 | The Regents Of The University Of Michigan | Process for alleviating proliferative skin diseases |
| DE2847975A1 (de) * | 1978-11-04 | 1980-05-14 | Merck Patent Gmbh | Verfahren zur bindung von freiem formaldehyd in pharmazeutischen und kosmetischen zubereitungen |
-
1980
- 1980-10-15 GB GB8033218A patent/GB2080106B/en not_active Expired
-
1981
- 1981-07-17 DE DE8181105635T patent/DE3163982D1/de not_active Expired
- 1981-07-17 MC MC811529A patent/MC1408A1/xx unknown
- 1981-07-17 CA CA000381977A patent/CA1172169A/en not_active Expired
- 1981-07-17 AT AT0318081A patent/AT381025B/de not_active IP Right Cessation
- 1981-07-17 GR GR65549A patent/GR75104B/el unknown
- 1981-07-17 CS CS815507A patent/CS229674B2/cs unknown
- 1981-07-17 PH PH25929A patent/PH16308A/en unknown
- 1981-07-17 IT IT48925/81A patent/IT1171399B/it active Protection Beyond IP Right Term
- 1981-07-17 AU AU73073/81A patent/AU547391B2/en not_active Expired
- 1981-07-17 CY CY1309A patent/CY1309A/xx unknown
- 1981-07-17 HU HU812097A patent/HU185936B/hu not_active IP Right Cessation
- 1981-07-17 IL IL63351A patent/IL63351A/xx not_active IP Right Cessation
- 1981-07-17 FI FI812257A patent/FI76255C/fi not_active IP Right Cessation
- 1981-07-17 IE IE1617/81A patent/IE51120B1/en not_active IP Right Cessation
- 1981-07-17 NO NO812464A patent/NO155038C/no unknown
- 1981-07-17 PT PT73391A patent/PT73391B/pt unknown
- 1981-07-17 BG BG052984A patent/BG60450B2/bg unknown
- 1981-07-17 DD DD81231891A patent/DD203464A5/de unknown
- 1981-07-17 ES ES504046A patent/ES504046A0/es active Granted
- 1981-07-17 PL PL1981232259A patent/PL135416B1/pl unknown
- 1981-07-17 ZW ZW171/81A patent/ZW17181A1/xx unknown
- 1981-07-17 AR AR286131A patent/AR225680A1/es active
- 1981-07-17 EP EP81105635A patent/EP0044543B1/en not_active Expired
- 1981-07-17 DK DK321681A patent/DK149191C/da active
- 1981-07-17 NZ NZ197744A patent/NZ197744A/xx unknown
-
1982
- 1982-07-17 RO RO82104911A patent/RO82678A/ro unknown
-
1985
- 1985-10-05 SG SG720/85A patent/SG72085G/en unknown
- 1985-11-28 HK HK954/85A patent/HK95485A/en not_active IP Right Cessation
-
1986
- 1986-12-30 MY MY389/86A patent/MY8600389A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI76255B (fi) | Foerfarande foer framstaellning av en antiviral foerbaettrad topisk olja-i-vatten-komposition av 9-(2-hydroxietoximetyl)guanin eller ett farmaceutiskt godtagbart salt eller ester daerav. | |
| CA1228812A (en) | Process for the manufacture of novel topically administrable pharmaceutical compositions | |
| US4963555A (en) | Formulations of heterocyclic compounds | |
| US5540934A (en) | Compositions for applying active substances to or through the skin | |
| EP0662819B1 (en) | An antivirally active pharmaceutical oil-in-water emulsion containing 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) or a salt or ester thereof | |
| JP5548275B2 (ja) | ビタミンｄ類似体および共溶媒−界面活性剤混合物から成る医薬品組成物 | |
| JP5732471B2 (ja) | 溶媒混合物およびビタミンｄ誘導体から成る医薬品組成物または類似体 | |
| EP0095813A2 (en) | Penetrating topical pharmaceutical compositions containing 9-(2-hydroxyethoxymethyl) guanine | |
| WO2000001390A1 (en) | Topical aciclovir formulations | |
| US20220152033A1 (en) | Compositions and methods for deep dermal drug delivery | |
| JP2025001042A (ja) | Ｊａｋ阻害剤およびラウレス－４を含有する局所配合物 | |
| CN115298190A (zh) | 离子液体、溶剂、制剂及经皮吸收剂 | |
| KR20180100596A (ko) | 사이클로스포린 a 국소성 조성물 | |
| AP197A (en) | Pharmaceutical formulations for treatment of virus infections of the skin containing penciclovir. | |
| IE902819A1 (en) | Pharmaceutical formulation | |
| US6469015B1 (en) | Pharmaceutical formulation | |
| Sigit Prakoeswa et al. | Skin Penetration of Topical Epigallocatechin-3-Gallate (EGCG) as an Alternative Agent for Photoaging Prevention. | |
| JP2002302433A (ja) | 低刺激性クリーム剤 | |
| WO2019002362A1 (en) | TOPICAL COMPOSITIONS OF CYCLOSPORIN A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |
Owner name: THE WELLCOME FOUNDATION LIMITED |